Recent advances in the treatment of life-threatening, invasive fungal infections

Bibliography

• Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39(3):309-17
   PubMed Web of Science ®Google Scholar
• Azie N, Neofytos D, Pfaller M, et al. The PATH (Prospective Antifungal Therapy) Alliance® registry and invasive fungal infections: update 2012. Diag Micro Infect Dis 2012;73(4):293-300
   PubMed Web of Science ®Google Scholar
• Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010;50(8):1101-11
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 2004;42(10):4419-31
   PubMed Web of Science ®Google Scholar
• Hahn-Ast C, Glasmacher A, Muckter S, et al. Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006. J Antimicrob Chemother 2010;65(4):761-8
   PubMed Web of Science ®Google Scholar
• Menzin J, Meyers JL, Friedman M, et al. The economic costs to United States hospitals of invasive fungal infections in transplant patients. Am J Infect Control 2011;39(4):e15-20
   PubMed Web of Science ®Google Scholar
• Ashley ED, Drew R, Johnson M, et al. Cost of invasive fungal infections in the era of new diagnostics and expanded treatment options. Pharmacother 2012;32(10):890-901
   PubMed Web of Science ®Google Scholar
• Chow JK, Golan Y, Ruthazer R, et al. Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit. Clin Infect Dis 2008;46(8):1206-13
   PubMed Web of Science ®Google Scholar
• Lortholary O, Desnos-Ollivier M, Sitbon K, et al. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother 2011;55(2):532-8
   PubMed Web of Science ®Google Scholar
• Alexander BD, Johnson MD, Pfeiffer CD, et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 2013;56(12):1724-32
   PubMed Web of Science ®Google Scholar
• Clancy CJ, Nguyen MH. Finding the "missing 50%" of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis 2013;56(9):1284-92
   PubMed Web of Science ®Google Scholar
• Safdar N, Smith J, Knasinski V, et al. Infections after the use of alemtuzumab in solid organ transplant recipients: a comparative study. Diagn Microbiol Infect Dis 2010;66(1):7-15
   PubMed Web of Science ®Google Scholar
• Spellberg B, Ibrahim AS, Chin-Hong PV, et al. The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother 2012;67(3):715-22
   PubMed Web of Science ®Google Scholar
• Garcia X, Mian A, Mendiratta P, et al. Aspergillus infection and extracorporeal membrane oxygenation support. J Inten Care Med 2013;28(3):178-84
   PubMed Web of Science ®Google Scholar
• Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006;43(1):25-31
   PubMed Web of Science ®Google Scholar
• Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005;49(9):3640-5
   PubMed Web of Science ®Google Scholar
• Kollef M, Micek S, Hampton N, et al. Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis 2012;54(12):1739-46
   PubMed Web of Science ®Google Scholar
• Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008;47(4):503-9
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48(5):503-35
   PubMed Web of Science ®Google Scholar
• Verweij P, Figueroa J, Van Burik J, et al. Clinical applications of nonculture based methods for the diagnosis and management of opportunistic and endemic mycoses. Med Mycol 2000;38:161-71
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L. Invasive mycoses: diagnostic challenges. Am J Med 2012;125(1 Suppl):S14-24
   PubMed Web of Science ®Google Scholar
• Nguyen MH, Clancy CJ. Biomarkers for diagnosis of candidal infections. Curr Fungal Infect Rep 2012;6:56-62
   Google Scholar
• White P, Perry M, Barnes R. An update on the molecular diagnosis of invasive fungal disease. FEMS Microbiol Lett 2009;296(1):1-10
   PubMed Web of Science ®Google Scholar
• Kourkoumpetis TK, Fuchs BB, Coleman JJ, et al. Polymerase chain reaction-based assays for the diagnosis of invasive fungal infections. Clin Infect Dis 2012;54(9):1322-31
   PubMed Web of Science ®Google Scholar
• Chang SS, Hsieh WH, Liu TS, et al. Multiplex PCR system for rapid detection of pathogens in patients with presumed sepsis – a systemic review and meta-analysis. PLoS ONE 2013;8(5):e62323
   PubMed Web of Science ®Google Scholar
• Avni T, Leibovici L, Paul M. PCR diagnosis of invasive candidiasis: systematic review and meta-analysis. J Clin Microbiol 2011;49(2):665-70
   PubMed Web of Science ®Google Scholar
• Neely LA, Audeh M, Phung NA, et al. T2 magnetic resonance enables nanoparticle-mediated rapid detection ofcandidemia in whole blood. Sci Transl Med 2013;5:182ra54
   PubMed Web of Science ®Google Scholar
• Wilson DA, Joyce MJ, Hall LS, et al. Multicenter evaluation of a Candida albicans peptide nucleic acid fluorescent in situ hybridization probe for characterization of yeast isolates from blood cultures. J Clin Microbiol 2005;43(6):2909-12
   PubMed Web of Science ®Google Scholar
• Hall L, Le Febre KM, Deml SM, et al. Evaluation of the yeast traffic light PNA FISH probes for identification of Candida species from positive blood cultures. J Clin Microbiol 2012;50(4):1446-8
   PubMed Web of Science ®Google Scholar
• Alexander BD, Ashley ED, Reller LB, et al. Cost savings with implementation of PNA FISH testing for identification of Candida albicans in blood cultures. Diagn Microbiol Infect Dis 2006;54(4):277-82
   PubMed Web of Science ®Google Scholar
• Shepard JR, Addison RM, Alexander BD, et al. Multicenter evaluation of the Candida albicans/Candida glabrata peptide nucleic acid fluorescent in situ hybridization method for simultaneous dual-color identification of C. albicans and C. glabrata directly from blood culture bottles. J Clin Microbiol 2008;46(1):50-5
   PubMed Web of Science ®Google Scholar
• Murray PR. Rapid identification of clinical yeast isolates by mass spectrometry. Curr Fungal Infect Rep 2010;4(3):145-50
   Google Scholar
• Buchan BW, Ledeboer NA. Advances in identification of clinical yeast isolates by use of matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol 2013;51(5):1359-66
   PubMed Web of Science ®Google Scholar
• Spanu T, Posteraro B, Fiori B, et al. Direct maldi-tof mass spectrometry assay of blood culture broths for rapid identification of Candida species causing bloodstream infections: an observational study in two large microbiology laboratories. J Clin Microbiol 2012;50(1):176-9
   PubMed Web of Science ®Google Scholar
• Marinach C, Alanio A, Palous M, et al. MALDI-TOF MS-based drug susceptibility testing of pathogens: the example of Candida albicans and fluconazole. Proteomics 2009;9(20):4627-31
   PubMed Web of Science ®Google Scholar
• Dhiman N, Hall L, Wohlfiel SL, et al. Performance and cost analysis of matrix-assisted laser desorption ionization-time of flight mass spectrometry for routine identification of yeast. J Clin Microbiol 2011;49(4):1614-16
   PubMed Web of Science ®Google Scholar
• Obayashi T, Yoshida M, Mori T, et al. Plasma (1–>3)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 1995;345(8941):17-20
   PubMed Web of Science ®Google Scholar
• Karageorgopoulos DE, Vouloumanou EK, Ntziora F. et al. beta-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis 2011;52(6):750-70
   PubMed Web of Science ®Google Scholar
• Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004;39(2):199-205
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1–>3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005;41(5):654-9
   PubMed Web of Science ®Google Scholar
• Obayashi T, Negishi K, Suzuki T, et al. Reappraisal of the serum (1–>3)-beta-D-glucan assay for the diagnosis of invasive fungal infections–a study based on autopsy cases from 6 years. Clin Infect Dis 2008;46(12):1864-70
   PubMed Web of Science ®Google Scholar
• Ohata A, Usami M, Horiuchi T, et al. Release of (1–>3)-beta-D-glucan from depth-type membrane filters and their in vitro effects on proinflammatory cytokine production. Artif Organs 2003;27(8):728-35
   PubMed Web of Science ®Google Scholar
• Marty FM, Lowry CM, Lempitski SJ, et al. Reactivity of (1–>3)-beta-d-glucan assay with commonly used intravenous antimicrobials. Antimicrob Agents Chemother 2006;50(10):3450-3
   PubMed Web of Science ®Google Scholar
• Kanamori H, Kanemitsu K, Miyasaka T, et al. Measurement of (1-3)-beta-D-glucan derived from different gauze types. Tohoku J Exp Med 2009;217(2):117-21
   PubMed Web of Science ®Google Scholar
• Senn L, Robinson JO, Schmidt S, et al. 1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis 2008;46(6):878-85
   PubMed Web of Science ®Google Scholar
• Maertens J, Theunissen K, Lodewyck T, et al. Advances in the serological diagnosis of invasive Aspergillus infections in patients with haematological disorders. Mycoses 2007;50(Suppl 1):2-17
   PubMed Web of Science ®Google Scholar
• Maertens J, Verhaegen J, Lagrou K, et al. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001;97(6):1604-10
   PubMed Web of Science ®Google Scholar
• Marr KA, Laverdiere M, Gugel A, et al. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005;40(12):1762-9
   PubMed Web of Science ®Google Scholar
• Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006;42(10):1417-27
   PubMed Web of Science ®Google Scholar
• Leeflang MM, Debets-Ossenkopp YJ, Visser CE, et al. Galactomannan detection for invasive aspergillosis in immunocompromized patients. Cochrane Database Syst Rev 2008(4):CD007394
   PubMed Web of Science ®Google Scholar
• Penack O, Rempf P, Graf B, et al. False-positive Aspergillus antigen testing due to application of piperacillin/tazobactam–is it still an issue? Diagn Microbiol Infect Dis 2008;60(1):117-20
   PubMed Web of Science ®Google Scholar
• Singh N, Obman A, Husain S, et al. Reactivity of platelia Aspergillus galactomannan antigen with piperacillin-tazobactam: clinical implications based on achievable concentrations in serum. Antimicrob Agents Chemother 2004;48(6):1989-92
   PubMed Web of Science ®Google Scholar
• Hsu JL, Ruoss SJ, Bower ND, et al. Diagnosing invasive fungal disease in critically ill patients. Crit Rev Microbiol 2011;37(4):277-312
   PubMed Web of Science ®Google Scholar
• Mengoli C, Cruciani M, Barnes RA, et al. Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. Lancet Infect Dis 2009;9(2):89-96
   PubMed Web of Science ®Google Scholar
• Florent M, Katsahian S, Vekhoff A, et al. Prospective evaluation of a polymerase chain reaction-ELISA targeted to Aspergillus fumigatus and Aspergillus flavus for the early diagnosis of invasive aspergillosis in patients with hematological malignancies. J Infect Dis 2006;193(5):741-7
   PubMed Web of Science ®Google Scholar
• Scotter JM, Campbell P, Anderson TP, et al. Comparison of PCR-ELISA and galactomannan detection for the diagnosis of invasive aspergillosis. Pathology 2005;37(3):246-53
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Berceanu A. Beta-D-glucan detection test: a step toward preemptive therapy for fungal infections in leukemic patients? Clin Infect Dis 2008;46(6):886-9
   PubMed Web of Science ®Google Scholar
• Einsele H, Loeffler J. Contribution of new diagnostic approaches to antifungal treatment plans in high-risk haematology patients. Clin Microbiol Infect 2008;14(Suppl 4):37-45
   PubMed Web of Science ®Google Scholar
• Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005;41(9):1242-50
   PubMed Web of Science ®Google Scholar
• Jaijakul S, Vazquez JA, Swanson RN, et al. (1,3)-beta-D-glucan as a prognostic marker of treatment response in invasive candidiasis. Clin Infect Dis 2012;55(4):521-6
   PubMed Web of Science ®Google Scholar
• Koo S, Baden LR, Marty FM. Post-diagnostic kinetics of the (1 –> 3)-beta-D-glucan assay in invasive aspergillosis, invasive candidiasis and Pneumocystis jirovecii pneumonia. Clin Microbiol Infect 2012;18(5):E122-7
   PubMed Web of Science ®Google Scholar
• Sims CR, Jaijakul S, Mohr J, et al. Correlation of clinical outcomes with beta-glucan levels in patients with invasive candidiasis. J Clin Microbiol 2012;50(6):2104-6
   PubMed Web of Science ®Google Scholar
• Nouer SA, Nucci M, Kumar NS, et al. Earlier response assessment in invasive aspergillosis based on the kinetics of serum Aspergillus galactomannan: proposal for a new definition. Clin Infect Dis 2011;53(7):671-6
   PubMed Web of Science ®Google Scholar
• Bergeron A, Porcher R, Menotti J, et al. Prospective evaluation of clinical and biological markers to predict the outcome of invasive pulmonary aspergillosis in hematological patients. J Clin Microbiol 2012;50(3):823-30
   PubMed Web of Science ®Google Scholar
• Chai LY, Kullberg BJ, Johnson EM, et al. Early serum galactomannan trend as a predictor of outcome of invasive aspergillosis. J Clin Microbiol 2012;50(7):2330-6
   PubMed Web of Science ®Google Scholar
• Krishna G, Ma L, Martinho M, et al. A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers. J Antimicrob Chemother 2012;67(11):2725-30
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Pharmacokinetics, safety, and tolerability of intravenous posaconazole solution followed by oral posaconazole suspension in subjects at high risk for invasive fungal infections (NCT01075984). Available from: ClinicalTrials.gov [Last accessed 18 June 2013]
   Google Scholar
• Pfaller MA, Messer SA, Hollis RJ, et al. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob Agents Chemother 2002;46(6):1723-7
   PubMed Web of Science ®Google Scholar
• Diekema DJ, Messer SA, Hollis RJ, et al. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003;41(8):3623-6
   PubMed Web of Science ®Google Scholar
• Andes D, Marchillo K, Stamstad T, et al. In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model. Antimicrob Agents Chemother 2003;47(4):1193-9
   PubMed Web of Science ®Google Scholar
• Yan JH, Marino MR, Smith RA, et al. The effect of ravuconazole on the pharmacokinetics of nelfinavir in healthy male volunteers. J.Clin.Pharmacol 2006;46(2):193-200
   PubMed Web of Science ®Google Scholar
• Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation. 2013. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00064311?term=ravuconazole&rank=1 [Accessed 28 February 2013]
   Google Scholar
• Guinea J, Pelaez T, Recio S, et al. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother 2008;52(4):1396-400
   PubMed Web of Science ®Google Scholar
• Illnait-Zaragozi MT, Martinez GF, Curfs-Breuker I, et al. In vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. Antimicrob Agents Chemother 2008;52(4):1580-2
   PubMed Web of Science ®Google Scholar
• Warn PA, Sharp A, Parmar A, et al. Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. Antimicrob Agents Chemother 2009;53(8):3453-61
   PubMed Web of Science ®Google Scholar
• Schmitt-Hoffmann A, Roos B, Maares J, et al. Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother 2006;50(1):286-93
   PubMed Web of Science ®Google Scholar
• Schmitt-Hoffmann A, Roos B, Spickermann J, et al. Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557. Antimicrob Agents Chemother 2009;53(11):4885-90
   PubMed Web of Science ®Google Scholar
• Viljoen JJ, Mitha I, Heep M, et al.Efficacy, safety, and tolerability of three different dosing regimens of BAL8557 vs. fluconazole in a double-blind, randomized, multicenter trial of the treatment of esophageal candidiasis in immunocompromised adults [abstract LB2-32. 2005]. Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 16 – 19 December 2005; Washington, DC; 2005
   Google Scholar
• Capilla J, Ortoneda M, Pastor FJ, et al. In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi. Antimicrob Agents Chemother 2001;45(9):2635-7
   PubMed Web of Science ®Google Scholar
• Morera-Lopez Y, Torres-Rodriguez JM, Jimenez-Cabello T, et al. Cryptococcus gattii: in vitro susceptibility to the new antifungal albaconazole versus fluconazole and voriconazole. Med Mycol 2005;43(6):505-10
   PubMed Web of Science ®Google Scholar
• Ramos G, Cuenca-Estrella M, Monzon A, et al. In vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of. Candida spp. J Antimicrob Chemother 1999;44(2):283-6
   PubMed Web of Science ®Google Scholar
• Brzankalski GE, Najvar LK, Wiederhold NP, et al. Evaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility. J Antimicrob Chemother 2008;62(5):1094-100
   PubMed Web of Science ®Google Scholar
• Isham N, Ghannoum MA. Determination of MICs of aminocandin for Candida spp. and filamentous fungi. J Clin Microbiol 2006;44(12):4342-4
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Motyl MR, et al. Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST). J Antimicrob Chemother 2013;68(4):858-63
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Motyl MR, et al. In vitro activity of a new oral slucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods. Antimicrob Agents Chemother 2013;57(2):1065-8
   PubMed Web of Science ®Google Scholar
• Motyl MR, Tan C, Liberator P, et al. MK-3118, an oral enfumafungin with potent in vitro activity against Candida and Aspergillus spp. [abstract F1-847]. Proceedings and abstracts of the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, DC; 12 – 15 September 2010; Boston: MA: 2010
   Google Scholar
• Heasley BH, Pacofsky GJ, Mamai A, et al. Synthesis and biological evaluation of antifungal derivatives of enfumafungin as orally bioavailable inhibitors of beta-1,3-glucan synthase. Bioorg Med Chem Lett 2012;22(22):6811-16
   PubMed Web of Science ®Google Scholar
• Miyazaki M, Horii T, Hata K, et al. In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds. Antimicrob Agents Chemother 2011;55(10):4652-8
   PubMed Web of Science ®Google Scholar
• Hata K, Horii T, Miyazaki M, et al. Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosis. Antimicrob Agents Chemother 2011;55(10):4543-51
   PubMed Web of Science ®Google Scholar
• Shibata T, Takahashi T, Yamada E, et al. T-2307 causes collapse of mitochondrial membrane potential in yeast. Antimicrob Agents Chemother 2012;56(11):5892-7
   PubMed Web of Science ®Google Scholar
• Mitsuyama J, Nomura N, Hashimoto K, et al. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine. Antimicrob Agents Chemother 2008;52(4):1318-24
   PubMed Web of Science ®Google Scholar
• Yamada E, Nishikawa H, Nomura N, et al. T-2307 shows efficacy in a murine model of Candida glabrata infection despite in vitro trailing growth phenomena. Antimicrob Agents Chemother 2010;54(9):3630-4
   PubMed Web of Science ®Google Scholar
• Karwa R, Wargo KA. Efungumab: a novel agent in the treatment of invasive candidiasis. Ann Pharmacother 2009;43(11):1818-23
   PubMed Web of Science ®Google Scholar
• Hodgetts S, Nooney L, Al-Akeel R, et al. Efungumab and caspofungin: pre-clinical data supporting synergy. J Antimicrob Chemother 2008;61(5):1132-9
   PubMed Web of Science ®Google Scholar
• Pachl J, Svoboda P, Jacobs F, et al. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 2006;42(10):1404-13
   PubMed Web of Science ®Google Scholar
• Ibrahim AS, Gebremariam T, French SW, et al. The iron chelator deferasirox enhances liposomal amphotericin B efficacy in treating murine invasive pulmonary aspergillosis. J Antimicrob Chemother 2010;65(2):289-92
   PubMed Web of Science ®Google Scholar
• Spellberg B, Andes D, Perez M. Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. Antimicrob Agents Chemother 2012;53:3122-5
   Google Scholar
• Safdar A. Immunotherapy for invasive mold disease in severely immunosuppressed patients. Clin Infect Dis 2013;57(1):94-100
   PubMed Web of Science ®Google Scholar
• Pappas PG, Bustamante B, Ticona E, et al. Recombinant interferon- gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J Infect Dis 2004;189(12):2185-91
   PubMed Web of Science ®Google Scholar
• Jarvis JN, Meintjes G, Rebe K, et al. Adjunctive interferon-gamma immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. AIDS 2012;26(9):1105-13
   PubMed Web of Science ®Google Scholar
• Clancy CJ, Yu VL, Morris AJ, et al. Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob Agents Chemother 2005;49(8):3171-7
   PubMed Web of Science ®Google Scholar
• Lewis RE. Current concepts in antifungal pharmacology. Mayo Clin Proc 2011;86(8):805-17
   PubMed Web of Science ®Google Scholar
• Pai MP, Turpin RS, Garey KW. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother 2007;51(1):35-9
   PubMed Web of Science ®Google Scholar
• Beyda ND, Lewis RE, Garey KW. Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches. Ann Pharmacother 2012;46(7-8):1086-96
   PubMed Web of Science ®Google Scholar
• Cornely OA, Vehreschild JJ, Vehreschild MJ, et al. Phase II dose escalation study of caspofungin for invasive aspergillosis. Antimicrob Agents Chemother 2011;55(12):5798-803
   PubMed Web of Science ®Google Scholar
• de WN, Llanos-Cuentas A, Suleiman J, et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004;39(6):842-9
   PubMed Web of Science ®Google Scholar
• Pettengell K, Mynhardt J, Kluyts T, et al. Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment.Pharmacol.Ther 2004;20(4):475-81
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Najvar LK, Bocanegra RA, et al. Caspofungin dose escalation for invasive candidiasis due to resistant Candida albicans. Antimicrob Agents Chemother 2011;55(7):3254-60
   PubMed Web of Science ®Google Scholar
• Slater JL, Howard SJ, Sharp A, et al. Disseminated candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin. Antimicrob Agents Chemother 2011;55(7):3075-83
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Najvar LK, Bocanegra R, et al. In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. Antimicrob Agents Chemother 2007;51(5):1616-20
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007;44(10):1289-97
   PubMed Web of Science ®Google Scholar
• Ellis M, Bernsen R, Ali-Zadeh H, et al. A safety and feasibility study comparing an intermittent high dose with a daily standard dose of liposomal amphotericin B for persistent neutropenic fever. J Med Microbiol 2009;58(Pt 11):1474-85
   PubMed Web of Science ®Google Scholar
• Falci DR, dos Santos RP, Wirth F, et al. Continuous infusion of amphotericin B deoxycholate: an innovative, low-cost strategy in antifungal treatment. Mycoses 2011;54(2):91-8
   PubMed Web of Science ®Google Scholar
• Falci DR, Lunardi LW, Ramos CG, et al. Continuous infusion of amphotericin B deoxycholate in the treatment of cryptococcal meningoencephalitis: analysis of safety and fungicidal activity. Clin Infect Dis 2010;50(5):e26-9
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L. Combination antifungal therapy: a critical review of the evidence. Clin Microbiol Infect 2008;14(Suppl 4):65-70
   PubMed Web of Science ®Google Scholar
• Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010;50(3):291-322
   PubMed Web of Science ®Google Scholar
• Day JN, Chau TT, Wolbers M, et al. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med 2013;368(14):1291-302
   PubMed Web of Science ®Google Scholar
• Spellberg B, Ibrahim A, Roilides E, et al. Combination therapy for mucormycosis: why, what, and how? Clin Infect Dis 2012;54(Suppl 1):S73-S8
   PubMed Web of Science ®Google Scholar
• Marr KA, Schlamm H, Rottinghaus ST, et al. A randomised, double-blind study of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis. 22nd European Congress of Clinical Microbiology and Infectious Diseases; March 31 – April 3 2012; London, England
   Google Scholar
• Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46(3):327-60
   PubMed Web of Science ®Google Scholar
• Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009;53(1):24-34
   PubMed Web of Science ®Google Scholar
• Boogaerts MA, Verhoef GE, Zachee P, et al. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses 1989;32(Suppl 1):103-8
   PubMed Web of Science ®Google Scholar
• Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008;46(2):201-11
   PubMed Web of Science ®Google Scholar
• Chu HY, Jain R, Xie H, et al. Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events. BMC Infect Dis 2013;13(1):105
   PubMed Web of Science ®Google Scholar
• Dolton MJ, Ray JE, Marriott D, et al. Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob.Agents Chemother 2012;56(6):2806-13
   PubMed Web of Science ®Google Scholar
• Mitsani D, Nguyen MH, Shields RK, et al. Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity. Antimicrob Agents Chemother 2012;56(5):2371-7
   PubMed Web of Science ®Google Scholar
• Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002;34(5):563-71
   PubMed Web of Science ®Google Scholar
• Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob.Agents Chemother 2006;50(4):1570-2
   PubMed Web of Science ®Google Scholar
• Trifilio S, Pennick G, Pi J, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007;109(8):1532-5
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007;44(1):2-12
   PubMed Web of Science ®Google Scholar
• Ananda-Rajah MR, Slavin MA, Thursky KT. The case for antifungal stewardship. Curr Opin Infect Dis 2012;25(1):107-15
   PubMed Web of Science ®Google Scholar